#USA #Alzheimer’s Disease #TML-6 #MerryLife #Tainan City

MerryLife Biomedical Advances Alzheimer's Research with TML-6

MerryLife Biomedical Inc., a pioneering biotechnology firm dedicated to tackling neurodegenerative diseases, has recently announced promising results from the Phase 1 clinical trial of TML-6, its novel oral therapy aimed at Alzheimer’s disease (AD). The findings indicate that TML-6 is generally well tolerated and possesses a favorable safety profile, instigating plans for a global Phase 2 trial to commence shortly.

Positive Results from Phase 1 Trials

The initial trials demonstrated TML-6's capacity to modulate complex biological processes critical to neurodegeneration. By affecting the autolysosomal system and the interrelated cellular pathways responsible for protein clearance, neuroinflammation, oxidative stress, and age-induced neuronal dysfunction, TML-6 may provide an essential multi-target approach to treat Alzheimer’s and Parkinson's diseases.

Launching the Global Phase 2 Trial

Encouraged by the Phase 1 outcomes, MerryLife is gearing up to launch an extensive Phase 2 trial involving approximately 210 participants, primarily focused on individuals experiencing mild cognitive impairment or mild dementia. This trial will span across various countries, including the United States, Sweden, and Taiwan, aiming to further assess safety, tolerability, and the potential for influencing disease-related biomarkers integral to multi-pathway modulation.

Broader Applications in Neurodegenerative Diseases

In addition to its focus on Alzheimer’s disease, MerryLife is also exploring the implications of TML-6 within Parkinson's disease, where parallel pathological mechanisms underlie disease development. Insights and relevant data related to TML-6's efficacy are expected to be presented at the upcoming AD/PD™ 2026 International Conference scheduled for March 19, 2026, in Copenhagen.

A Multi-Targeted Approach to Neurodegeneration

“Neurodegenerative disorders like Alzheimer’s and Parkinson’s arise from intricate biological processes that are often resistant to traditional single-target therapies,” explains Dr. Ih-Jen Su, CEO of MerryLife Biomedical. “TML-6 represents a holistic approach with an oral delivery mechanism and a promising safety profile, allowing for earlier interventions that could potentially decelerate disease progression in areas with unmet medical necessities.”

About TML-6 and MerryLife Biomedical Inc.

TML-6 is classified as a first-in-class investigational therapy, distinguished by its oral administration and multi-targeted design aimed at regulating crucial autolysosomal and aging-related pathways linked to neurodegenerative disorders. MerryLife Biomedical is committed to developing groundbreaking therapies in the field of neurodegeneration, with the core objective of redefining treatment paradigms centered on aging and disease-related biological pathways.

As we anticipate further developments in the Phase 2 trial, the scientific community looks forward to the innovative ways in which MerryLife Biomedical is set to make strides against Alzheimer’s and related diseases.